Trial Outcomes & Findings for Reducing Use of Sleep Medications Assisted by a Digital Insomnia Intervention (NCT NCT05027438)
NCT ID: NCT05027438
Last Updated: 2025-04-11
Results Overview
Total score (0-28): no insomnia (0-7); sub-threshold (8-14); moderate (15-21); and severe insomnia (22-28). A reduction pre- to post-treatment/follow-up of 8 points (or more) indicate a treatment response and a post-treatment/follow-up score or 7 (or less) indicate remission.
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
36 participants
Primary outcome timeframe
baseline (T0; week 0), post-treatment (T1; week 12), 3 month follow-up (T2; week 24)
Results posted on
2025-04-11
Participant Flow
Participant milestones
| Measure |
COAST + Deprescribing
CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
Cognitive Behavioral Therapy for Insomnia: A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
Deprescribing: The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
|
|---|---|
|
Intervention
STARTED
|
36
|
|
Intervention
COMPLETED
|
25
|
|
Intervention
NOT COMPLETED
|
11
|
|
Post-Treatment
STARTED
|
25
|
|
Post-Treatment
COMPLETED
|
24
|
|
Post-Treatment
NOT COMPLETED
|
1
|
|
3-month Follow-Up
STARTED
|
24
|
|
3-month Follow-Up
COMPLETED
|
19
|
|
3-month Follow-Up
NOT COMPLETED
|
5
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Reducing Use of Sleep Medications Assisted by a Digital Insomnia Intervention
Baseline characteristics by cohort
| Measure |
COAST + Deprescribing
n=36 Participants
CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
Cognitive Behavioral Therapy for Insomnia: A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
Deprescribing: The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
|
|---|---|
|
Age, Continuous
|
59.22 years
STANDARD_DEVIATION 13.97 • n=5 Participants
|
|
Sex: Female, Male
Female
|
3 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
33 Participants
n=5 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Black or African American
|
5 Participants
n=5 Participants
|
|
Race (NIH/OMB)
White
|
31 Participants
n=5 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
|
Marital Status
Married
|
23 Participants
n=5 Participants
|
|
Marital Status
Divorced
|
8 Participants
n=5 Participants
|
|
Marital Status
Never Married
|
3 Participants
n=5 Participants
|
|
Marital Status
Widowed
|
1 Participants
n=5 Participants
|
|
Marital Status
Unknown
|
1 Participants
n=5 Participants
|
|
Military Branch
Army
|
15 Participants
n=5 Participants
|
|
Military Branch
Marine Corps
|
8 Participants
n=5 Participants
|
|
Military Branch
Navy
|
6 Participants
n=5 Participants
|
|
Military Branch
Air Force
|
5 Participants
n=5 Participants
|
|
Military Branch
Coast Guard
|
1 Participants
n=5 Participants
|
|
Military Branch
Unknown
|
1 Participants
n=5 Participants
|
|
Combat Exposure
Yes
|
21 Participants
n=5 Participants
|
|
Combat Exposure
No
|
15 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: baseline (T0; week 0), post-treatment (T1; week 12), 3 month follow-up (T2; week 24)Population: intent to treat analysis - time frame sample size differs due to drop out
Total score (0-28): no insomnia (0-7); sub-threshold (8-14); moderate (15-21); and severe insomnia (22-28). A reduction pre- to post-treatment/follow-up of 8 points (or more) indicate a treatment response and a post-treatment/follow-up score or 7 (or less) indicate remission.
Outcome measures
| Measure |
COAST + Deprescribing
n=35 Participants
CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
Cognitive Behavioral Therapy for Insomnia: A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
Deprescribing: The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
|
COAST + Deprescribing - Post-Treatment
CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
Cognitive Behavioral Therapy for Insomnia: A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
Deprescribing: The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
|
COAST + Deprescribing - 3-Month Follow-Up
CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
Cognitive Behavioral Therapy for Insomnia: A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
Deprescribing: The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
|
|---|---|---|---|
|
Insomnia Severity Index (ISI) Change
Baseline
|
14.63 score on a scale
Standard Deviation 4.04
|
—
|
—
|
|
Insomnia Severity Index (ISI) Change
Post-Treatment
|
6.13 score on a scale
Standard Deviation 4.10
|
—
|
—
|
|
Insomnia Severity Index (ISI) Change
3-month Follow-Up
|
7.17 score on a scale
Standard Deviation 3.59
|
—
|
—
|
PRIMARY outcome
Timeframe: baseline (T0; week 0), post-treatment (T1; week 12), 3 month follow-up (T2; week 24)Population: intent to treat analysis - time frame sample size differs due to drop out
Change in dose % from baseline (T0; week 0) to post-treatment (T1; week 12) Change in dose % from baseline (T0; week 0) to 3-month follow-up (T2; week 24)
Outcome measures
| Measure |
COAST + Deprescribing
n=22 Participants
CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
Cognitive Behavioral Therapy for Insomnia: A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
Deprescribing: The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
|
COAST + Deprescribing - Post-Treatment
CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
Cognitive Behavioral Therapy for Insomnia: A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
Deprescribing: The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
|
COAST + Deprescribing - 3-Month Follow-Up
CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
Cognitive Behavioral Therapy for Insomnia: A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
Deprescribing: The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
|
|---|---|---|---|
|
Sedative-Hypnotic Medication Use Change
baseline
|
100 % medication dose relative to baseline
Standard Deviation 0
|
—
|
—
|
|
Sedative-Hypnotic Medication Use Change
post-treatment
|
41.45 % medication dose relative to baseline
Standard Deviation 43.98
|
—
|
—
|
|
Sedative-Hypnotic Medication Use Change
3-month follow-up
|
37.74 % medication dose relative to baseline
Standard Deviation 54.93
|
—
|
—
|
SECONDARY outcome
Timeframe: post-treatment (T1; week 12), 3 month follow-up (T2; week 24)Population: intent to treat analysis - time frame sample size differs due to drop out
Percentage of participants that stopped using sleep medications at post-treatment (T1; week 12) and 3-month follow-up (T2; week 24)
Outcome measures
| Measure |
COAST + Deprescribing
n=22 Participants
CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
Cognitive Behavioral Therapy for Insomnia: A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
Deprescribing: The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
|
COAST + Deprescribing - Post-Treatment
CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
Cognitive Behavioral Therapy for Insomnia: A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
Deprescribing: The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
|
COAST + Deprescribing - 3-Month Follow-Up
CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
Cognitive Behavioral Therapy for Insomnia: A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
Deprescribing: The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
|
|---|---|---|---|
|
Sedative-Hypnotic Medication Cessation
post-treatment
|
7 Participants
|
—
|
—
|
|
Sedative-Hypnotic Medication Cessation
3-month follow-up
|
12 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: baseline (T0; week 0), post-treatment (T1; week 12), 3 month follow-up (T2; week 24)Population: intent to treat analysis - time frame sample size differs due to drop out
The Sleep Diary measures common sleep variables important for tracking and changing sleep behaviors: Sleep Onset Latency (SOL) is the subjective estimate of time it takes to fall asleep after going to bed and turning the lights out (or attempting to go to sleep). SOL is measured in minutes (lower values are better).
Outcome measures
| Measure |
COAST + Deprescribing
n=36 Participants
CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
Cognitive Behavioral Therapy for Insomnia: A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
Deprescribing: The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
|
COAST + Deprescribing - Post-Treatment
CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
Cognitive Behavioral Therapy for Insomnia: A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
Deprescribing: The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
|
COAST + Deprescribing - 3-Month Follow-Up
CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
Cognitive Behavioral Therapy for Insomnia: A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
Deprescribing: The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
|
|---|---|---|---|
|
Sleep Diary - Sleep Onset Latency (SOL) Change
baseline
|
34.19 minutes
Standard Deviation 27.73
|
—
|
—
|
|
Sleep Diary - Sleep Onset Latency (SOL) Change
post-treatment
|
20.02 minutes
Standard Deviation 14.50
|
—
|
—
|
|
Sleep Diary - Sleep Onset Latency (SOL) Change
3-month follow-up
|
20.11 minutes
Standard Deviation 16.46
|
—
|
—
|
SECONDARY outcome
Timeframe: baseline (T0; week 0), post-treatment (T1; week 12), 3 month follow-up (T2; week 24)Population: intent to treat analysis - time frame sample size differs due to drop out
The Sleep Diary measures common sleep variables important for tracking and changing sleep behaviors: Wake After Sleep Onset (WASO) is the subjective estimate of time awake in the middle of the night, after falling asleep and before final rise time/out of bed. WASO is measured in minutes (lower values are better).
Outcome measures
| Measure |
COAST + Deprescribing
n=36 Participants
CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
Cognitive Behavioral Therapy for Insomnia: A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
Deprescribing: The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
|
COAST + Deprescribing - Post-Treatment
CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
Cognitive Behavioral Therapy for Insomnia: A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
Deprescribing: The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
|
COAST + Deprescribing - 3-Month Follow-Up
CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
Cognitive Behavioral Therapy for Insomnia: A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
Deprescribing: The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
|
|---|---|---|---|
|
Sleep Diary - Wake After Sleep Onset (WASO) Change
baseline
|
26.04 minutes
Standard Deviation 31.90
|
—
|
—
|
|
Sleep Diary - Wake After Sleep Onset (WASO) Change
post-treatment
|
14.68 minutes
Standard Deviation 14.96
|
—
|
—
|
|
Sleep Diary - Wake After Sleep Onset (WASO) Change
3-month follow-up
|
11.04 minutes
Standard Deviation 14.58
|
—
|
—
|
SECONDARY outcome
Timeframe: baseline (T0; week 0), post-treatment (T1; week 12), 3 month follow-up (T2; week 24)Population: intent to treat analysis - time frame sample size differs due to drop out
The Sleep Diary measures common sleep variables important for tracking and changing sleep behaviors: Sleep Efficiency (SE) = (total sleep time \[TST\] / time in bed \[TIB\]) x 100. SE is measured as a percentage (range 0-100%; higher values are better).
Outcome measures
| Measure |
COAST + Deprescribing
n=36 Participants
CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
Cognitive Behavioral Therapy for Insomnia: A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
Deprescribing: The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
|
COAST + Deprescribing - Post-Treatment
CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
Cognitive Behavioral Therapy for Insomnia: A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
Deprescribing: The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
|
COAST + Deprescribing - 3-Month Follow-Up
CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
Cognitive Behavioral Therapy for Insomnia: A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
Deprescribing: The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
|
|---|---|---|---|
|
Sleep Diary - Sleep Efficiency Change
baseline
|
87 sleep efficiency (%)
Standard Deviation 9
|
—
|
—
|
|
Sleep Diary - Sleep Efficiency Change
post-treatment
|
93 sleep efficiency (%)
Standard Deviation 5
|
—
|
—
|
|
Sleep Diary - Sleep Efficiency Change
3-month follow-up
|
94 sleep efficiency (%)
Standard Deviation 5
|
—
|
—
|
SECONDARY outcome
Timeframe: baseline (T0; week 0), post-treatment (T1; week 12), 3 month follow-up (T2; week 24)Population: intent to treat analysis - time frame sample size differs due to drop out
Includes constructs of Physical Function, Participation in Social Roles, Anxiety, Depression, Fatigue, Sleep Disturbance, Pain Interference and Intensity, and Cognitive Function. Constructs are scored individually (4 items, 4-20) except Cognitive Function (2 items, 2-10). T-score: population mean=50 and a standard deviation=10. A higher PROMIS T-score represents more of the concept being measured. For negatively-worded concepts like Anxiety, Depression, Sleep, Pain, and Fatigue, a T-score of 60 is one SD worse than average. By comparison, an Anxiety T-score of 40 is one SD better than average. However, for positively-worded concepts like Physical Function, Cognitive Function, and Social Roles, a T-score of 60 is one SD better than average while a T-score of 40 is one SD worse than average. When all constructs are scored together, a preference score is calculated, representing health-related quality of life ranging from 0 (as bad as dead) to 1 (perfect or ideal health).
Outcome measures
| Measure |
COAST + Deprescribing
n=36 Participants
CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
Cognitive Behavioral Therapy for Insomnia: A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
Deprescribing: The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
|
COAST + Deprescribing - Post-Treatment
n=24 Participants
CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
Cognitive Behavioral Therapy for Insomnia: A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
Deprescribing: The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
|
COAST + Deprescribing - 3-Month Follow-Up
n=15 Participants
CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
Cognitive Behavioral Therapy for Insomnia: A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
Deprescribing: The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
|
|---|---|---|---|
|
Patient-Reported Outcomes Measurement Information System Adult Profile (PROMIS 29+2) Change
Anxiety
|
51.58 T-score
Standard Deviation 8.18
|
48.48 T-score
Standard Deviation 8.51
|
48.39 T-score
Standard Deviation 7.96
|
|
Patient-Reported Outcomes Measurement Information System Adult Profile (PROMIS 29+2) Change
Cognitive Function
|
45.46 T-score
Standard Deviation 5.94
|
48.46 T-score
Standard Deviation 7.60
|
49.98 T-score
Standard Deviation 4.62
|
|
Patient-Reported Outcomes Measurement Information System Adult Profile (PROMIS 29+2) Change
Depression
|
50.74 T-score
Standard Deviation 8.77
|
49.08 T-score
Standard Deviation 8.32
|
46.75 T-score
Standard Deviation 6.01
|
|
Patient-Reported Outcomes Measurement Information System Adult Profile (PROMIS 29+2) Change
Fatigue
|
56.31 T-score
Standard Deviation 7.99
|
50.90 T-score
Standard Deviation 9.17
|
46.93 T-score
Standard Deviation 8.50
|
|
Patient-Reported Outcomes Measurement Information System Adult Profile (PROMIS 29+2) Change
Pain Interference/Intensity
|
57.74 T-score
Standard Deviation 6.93
|
56.53 T-score
Standard Deviation 7.41
|
53.23 T-score
Standard Deviation 6.38
|
|
Patient-Reported Outcomes Measurement Information System Adult Profile (PROMIS 29+2) Change
Physical Function
|
42.90 T-score
Standard Deviation 7.30
|
45.40 T-score
Standard Deviation 6.07
|
47.67 T-score
Standard Deviation 6.64
|
|
Patient-Reported Outcomes Measurement Information System Adult Profile (PROMIS 29+2) Change
Sleep Disturbance
|
58.48 T-score
Standard Deviation 6.11
|
50.10 T-score
Standard Deviation 6.29
|
49.99 T-score
Standard Deviation 5.22
|
|
Patient-Reported Outcomes Measurement Information System Adult Profile (PROMIS 29+2) Change
Ability to Participate in Social Roles
|
49.07 T-score
Standard Deviation 8.50
|
54.36 T-score
Standard Deviation 8.60
|
57.53 T-score
Standard Deviation 6.63
|
SECONDARY outcome
Timeframe: baseline (T0; week 0), post-treatment (T1; week 12), 3 month follow-up (T2; week 24)Population: intent to treat analysis - time frame sample size differs due to drop out
The PROMIS-29+2 Profile v2.1 (PROPr) is used to calculate a preference score (PROMIS Preference, PROPr). Preference-based scores provide an overall summary of health-related quality of life on a common metric. Preference-based scores summarize multiple domains on a metric ranging from 0 (as bad as dead) to 1 (perfect or ideal health). Scores can be used in comparisons across groups and for cost-utility analyses. The profile includes all items in the PROMIS-29 Profile v2.1 plus two Cognitive Function Abilities items. T-scores from the measure can be used to calculate a preference-based score.
Outcome measures
| Measure |
COAST + Deprescribing
n=36 Participants
CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
Cognitive Behavioral Therapy for Insomnia: A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
Deprescribing: The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
|
COAST + Deprescribing - Post-Treatment
n=24 Participants
CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
Cognitive Behavioral Therapy for Insomnia: A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
Deprescribing: The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
|
COAST + Deprescribing - 3-Month Follow-Up
n=14 Participants
CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
Cognitive Behavioral Therapy for Insomnia: A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
Deprescribing: The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
|
|---|---|---|---|
|
Patient-Reported Outcomes Measurement Information System Adult Profile (PROMIS 29+2) - PROMIS Preference (PROPr)
|
0.29 score 0-1
Standard Deviation 0.16
|
0.41 score 0-1
Standard Deviation 0.19
|
0.50 score 0-1
Standard Deviation 0.15
|
Adverse Events
COAST + Deprescribing
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Adam Bramoweth, PhD (Principal Investigator)
VA Pittsburgh Healthcare System
Phone: (412) 360-2806
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place